About — J.P. Hemp Company
Research Standards
This archive exists because the cannabinoid research landscape is genuinely interesting and genuinely difficult to read accurately without a guide. The science is real. The overclaiming is also real. Our job is to hold both things honestly — to document what the research has actually found, in whatever detail the evidence warrants, without inflating it toward conclusions it does not support and without dismissing it because it is inconvenient or commercially unhelpful.
What follows is a plain account of how we approach that job: how we decide what to include, how we assess evidence, how we handle the territory between a promising preclinical finding and a clinical claim, and how we maintain this archive over time.
How We Select Evidence
Every article in this archive is grounded in peer-reviewed published research. We do not cite proprietary studies, unpublished data, or company-commissioned research as primary evidence. Where a finding is widely reported but derives from a single study, we say so. Where a finding has been replicated across multiple independent research groups, we note that too — because replication changes what the evidence supports.
We apply a three-tier framework to all research findings. Tier 1 is human clinical trial data — randomized controlled trials, crossover studies, and observational research with human participants and measured outcomes. Tier 2 is preclinical evidence — animal models, cell culture studies, and receptor binding assays. Tier 3 is mechanistic inference — reasoning from known pharmacology to plausible effects without direct experimental support. Every article labels which tier or tiers its core claims occupy. We do not mix tiers without naming the distinction.
This framework means that CBG — the founding research compound of this company — is held to the same standard as every other cannabinoid. Its human trial data earns Tier 1 status in the domains where it exists. In the domains where only preclinical evidence exists, it is labeled Tier 2. We do not promote CBG beyond what its evidence base supports, even when the evidence base is our commercial foundation.
How We Handle Preclinical Evidence
Most cannabinoid research is preclinical. Cell culture studies and animal models are not evidence of clinical effect, but they are not worthless either — they document biological activity, identify mechanisms, and establish the scientific rationale for human investigation. We treat them as what they are: the beginning of a research question, not the answer to it.
When we document a preclinical finding, we describe the model used — because a mouse model of acute chemical colitis is a different thing from human Crohn's disease, and a keratinocyte cell line is a different thing from psoriatic skin. We name the route of administration, because intraperitoneal injection in a mouse and oral dosing in a human produce different concentrations at target tissue. We note when a mechanism has been identified versus when an effect has been observed without a confirmed mechanism. These distinctions are not caveats appended out of caution — they are the scientific content of the finding. A reader who understands them can evaluate the research accurately. A reader who does not cannot.
What We Do Not Publish
We do not make therapeutic claims. We do not write that any compound in this archive treats, manages, prevents, or cures any condition. We do not use language that implies clinical efficacy for conditions that have not been studied in controlled human trials. When the research establishes a documented effect in humans — as it does for CBD's anxiolytic activity and CBG's stress-reducing effects in naturalistic data — we describe what the studies found, in the terms the studies used, with the limitations the studies carried.
We do not publish articles in domains where CBG has no research and CBD's evidence is too thin to support meaningful discussion. A number of topics that appear in popular cannabinoid content — CBN as a sleep aid without controlled trial evidence, cannabinoids for weight loss, cannabinoids as an alternative to psychiatric medication — do not appear in this archive because the evidence does not warrant it, not because we are unaware of the claims.
We do not write FAQ sections, appended disclaimer blocks, or promotional calls to action within research articles. These formats serve marketing goals, not research communication. The archive is a research resource. Its structure reflects that.
How We Cite
Every research claim in this archive is linked to a specific published study in the references section at the end of each article. We cite the original research, not secondary summaries or press releases. Where a finding has been misrepresented in popular coverage — as CBN's sleep claim was misread from 1970s combination studies — we say so, naming the original research and the misreading. We do not reproduce copyrighted material from published papers; we describe and interpret findings in our own language.
We make a distinction throughout the archive between a finding and its implications. A study finding is what the researchers measured and observed. An implication is what we or others might infer from it. We keep these labeled separately because the inferential step from preclinical finding to human application is where most overclaiming occurs — and where the most important intellectual honesty is required.
How We Handle Emerging Research
Cannabinoid science is moving quickly. New studies publish regularly in every domain this archive covers. Our approach to emerging research is to update individual articles when new evidence materially changes the picture — either strengthening a claim from Tier 2 to Tier 1 as human trials appear, or qualifying an existing claim when new research complicates it. We do not remove references to prior studies unless they have been retracted. We add new findings in context, noting what they add to and what they change about the existing evidence picture.
Two articles in this archive are designated as PPL — planned post-launch — and will be written when specific external triggers occur. One awaits publication of an ongoing clinical trial examining CBG in a specific domain. One awaits a compliance review before we can responsibly cover the topic at all. We name these triggers explicitly because the absence of an article on a topic in this archive is sometimes a deliberate decision, not an oversight, and readers deserve to know the difference.
How We Review and Update
Each research article carries a "Last Reviewed" date. Annual review examines four things: whether new human trial data has published that upgrades a claim's evidence tier; whether new studies should be added to the references section; whether cross-links to other archive articles have become stale or need expanding; and whether any field notes documenting research gaps need updating because the gap has been filled. The evidence standards governing each article do not change at review — only the evidence picture.
Significant revisions — when new evidence substantially changes an article's core argument rather than adding to it — are handled as full writing sessions with the same standards that governed the original article. We record significant revisions in the internal audit that tracks this archive's editorial history.
How to Read Our Articles
Each article begins with a lede that frames the subject without summarizing it. The evidence tier tag — where present — tells you immediately whether the article's core findings come from human research or animal models. Field notes signal where important qualifications, derivative distinctions, or research gaps require special attention. The honest evidence summary at the end of most articles states plainly what the research has and has not established.
The archive is organized into pillars — collections of articles sharing a biological domain — with a pillar anchor article at the top of each one. If you are unfamiliar with a topic, starting with the anchor gives you the biological context the daughter articles assume. The Understanding section covers the endocannabinoid system, the plant, and research literacy — these articles are not prerequisites, but readers who have worked through them find the Health Topics content considerably more accessible.
We have tried to write every article for two audiences simultaneously: the research-curious reader with a scientific background who wants to evaluate the evidence carefully, and the general reader who wants to understand what the research means without needing a graduate degree to follow it. Where those goals create tension, we resolve it by explaining more, not by simplifying the science. The evidence is what it is. Our job is to make it legible.
This archive was built by J.P. Hemp Company's research and editorial team over the course of 2025 and 2026. It will continue to be maintained and updated as the science develops. Questions about our standards or specific articles can be directed through the contact page.
These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease.